Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.

Cervical Cancer Clinical Trial

— DiaVACCS  

Official title:

Primary HPV Screening as an Indicator of Cervical Pre-invasive and Invasive Neoplasia in HIV-positive and -Negative Southern African Women

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02956031
• Other study ID #: DiaVACCS
• Status: Recruiting
• Start date: December 2016
• Est. completion date: December 2038

Study information

• Verified date: May 2024
• Source: University of Pretoria
• Contact: Greta Dreyer, PhD
• Phone: +(27) 12 354 3900
• Email: greta.dreyer[@]up.ac.za
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Nearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year. Although the current prevalence of pre-cancer cervical disease is largely unknown, data from local studies suggest regional differences and an increase in the prevalence of cytological abnormalities when compared with historical data. Low frequency in cytology screening is the primary factor attributable to development of invasive cervical cancer and almost one-third of all cervical cancer patients had previous negative cytology. Due to the low sensitivity of cytology it can be assumed that the true prevalence of pre-cancer disease is underestimated by all available data. One round of optimal cervical cytology will detect around 50% of existing pre-cancer cervical disease as identified and proven using colposcopy and directed biopsy. It is now widely accepted that primary screening with a human papilloma virus (HPV) test can improve the sensitivity of screening and that even a single round of HPV screening can rapidly reduce the incidence of invasive cervical cancer and related mortality within a few years.

South Africa has a high prevalence of HIV infection and a delay in or failure to initiate antiretroviral therapy (ART). These facts, together with the largely unscreened status of the female population and the high incidence of cervical cancer all suggest that HPV infection and precursors to cervical cancer are both unusually common among South African women. Accurate current knowledge of the performance of newer generation HPV based screening tests in HIV-infected and general female population are essential for cost-analysis and planning for national prevention and screening programs. This study will aim to demonstrate the feasibility and efficacy of new generation HPV deoxyribonucleic acid (DNA) based screening assays in a South African setting.

The investigators hypothesize that HPV testing followed by normal and special cytology tests will be a successful screening model for a South African population.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1500
• Est. completion date: December 2038
• Est. primary completion date: December 2038
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 25 Years to 75 Years

Eligibility

Inclusion Criteria:

• Informed consent accepted and signed

• Health seeking behaviour or request for a cervical cancer screening test

• Willing and able to receive test result by automated text message or clinic visit

Exclusion Criteria:

• Current pregnancy

• Hysterectomy

• Current or previous treatment for gynaecological cancer

• Hesitant or unable to undergo screening and treatment if indicated

Related Conditions & MeSH terms

• Cervical Cancer
• CIN2
• High Grade Sil
• Uterine Cervical Neoplasms

Intervention

Other:
• Screening
Cervical specimen obtained using speculum examination and cervical collection bush.
• Colposcopy
Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.

Procedure:
• LLETZ
The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).

Locations

Country	Name	City	State
South Africa	Steve Biko Academic Hospital	Pretoria	Gauteng

Sponsors (2)

Lead Sponsor	Collaborator
University of Pretoria	University of Stellenbosch

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of women with histologically proven cervical intraepithelial neoplasia grade 2+ (CIN2+) detected using HPV DNA analysis with partial genotyping as primary screen test followed by cervical cytology and immunocytochemistry as triage tests		Detected on histology biopsy at colposcopy after initial HPV screening with simultaneous cytology and immunocytochemistry testing
Secondary	Number of women with CIN2+ detected using HPV DNA analysis with partial genotyping that is associated with HPV types 16, 18, 16 and/or 18, only other high risk types		Detected on histology biopsy at colposcopy after initial HPV screening with simultaneous cytology and immunocytochemistry testing